1. Statins reduce spirochetal burden and modulate immune responses in the C3H/HeN mouse model of Lyme disease
- Author
-
Janakiram Seshu, Robert L. Reddick, S. L. Rajasekhar Karna, Tricia A. Van Laar, Camaron R. Hole, Christine L. Miller, and Floyd L. Wormley
- Subjects
0301 basic medicine ,030106 microbiology ,Immunology ,Reductase ,Biology ,Microbiology ,Article ,03 medical and health sciences ,C3H/HeN Mouse ,Immune system ,Lyme disease ,medicine ,Animals ,Immunologic Factors ,Borrelia burgdorferi ,Lyme Disease ,Mice, Inbred C3H ,bacterial infections and mycoses ,medicine.disease ,biology.organism_classification ,Bacterial Load ,Anti-Bacterial Agents ,LYME ,Treatment Outcome ,030104 developmental biology ,Infectious Diseases ,Female ,Mevalonate pathway ,Cell wall biogenesis ,Hydroxymethylglutaryl-CoA Reductase Inhibitors - Abstract
Lyme disease (LD) is a systemic disorder caused by Borrelia burgdorferi. Lyme spirochetes encode for a functional 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGR EC 1.1.1.88) serving as a rate limiting enzyme of the mevalonate pathway that contribute to components critical for cell wall biogenesis. Statins have been shown to inhibit B. burgdorferi in vitro. Using a mouse model of Lyme disease, we found that statins contribute to reducing bacterial burden and altering the murine immune response to favor clearance of spirochetes.
- Published
- 2016
- Full Text
- View/download PDF